
|Articles|May 1, 2002
Intravesical gemcitabine promising for TCC
Bethesda, MD-Treatment with an intravesical formulation of gemcitabine(Gemzar) in patients with transitional cell carcinoma shows promise, accordingto results from a phase I trial. The findings were presented at the Societyof Urologic Oncology/National Cancer Institute second annual meeting here.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
3
Study suggests potential diuretic effect with nadofaragene firadenovec
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











